Skip to content

Live birth rate of epididymal versus testicular sperm for intracytoplasmic sperm injection in obstructive azoospermia: a multi-center prospective randomized controlled clinical trial

Live birth rate of epididymal versus testicular sperm for intracytoplasmic sperm injection in obstructive azoospermia: a multi-center prospective randomized controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034988
Enrollment
Unknown
Registered
2020-07-26
Start date
2021-01-01
Completion date
Unknown
Last updated
2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive azoospermia

Interventions

Testicular spermatozoa group:The spermatozoa are aspirated from testis by puncturing
Epididymal sperm group:The spermatozoa are aspirated from epididymis by puncturing

Sponsors

The Third Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
22 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1) Informed consent has been signed before enrollment; 2) The patient was clearly diagnosed as obstructive azoospermia, and more than one moving sperm /HPF are observed in epididymal puncture; 3) Patients are aged 22-40 years and going to be treated with ICSI; 4) The spouse are aged 20-35 years old with 3-20 eggs; 5) It is the first ICSI cycle of the subject.

Exclusion criteria

Exclusion criteria: 1) Couples planning to freeze all embryos due to hydrosalpinx requiring surgical treatment or high progesterone level on HCG day; 2) There are factors affecting the outcome of ICSI in the female, including but not limited to grade III-IV endometriosis, visible hydrosalpinx under B-ultrasound, recurrent abortion history; 3) Couples with known abnormal chromosomal karyotypes; 4) Couples diagnosed with any systemic disease with clinical symptoms; 5) Other IVF/ICSI contraindications; 6) The spouse is diagnosed with abnormal uterine morphology (confirmed by three-dimensional B-ultrasound or hysteroscopy), including uterine malformation (mediastinal uterus, single angle or double uterus), submucosal uterine fibroids or intramural myoma (greater than 5cm), or intrauterine adhesion; 7) IVM, egg-freezing, or PGT cycles; 8) The patient is currently participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Live birth rate;

Secondary

MeasureTime frame
Fertilization rate;Day 3 egg utilization rate;Implantation rate;Clinical pregnancy rate;Pregnancy loss rate;Neonatal birth weight;Sperm retrieval rate;Sex ratio at birth;

Countries

China

Contacts

Public ContactGeng An

The Third Affiliated Hospital of Guangzhou Medical University

523189456@qq.com+86 15915815665

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026